Glutamate NMDA receptor; GRIN1/GRIN2B · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Glutamate NMDA receptor; GRIN1/GRIN2B shows clinical signal disease relevance led by depressive disorder. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q05586. Start with depressive disorder, then reuse UniProt Q05586 as the stable protein anchor across project notes and exports.
Start with depressive disorder, then reuse UniProt Q05586 as the stable protein anchor across project notes and exports.
Glutamate NMDA receptor; GRIN1/GRIN2B shows clinical signal disease relevance led by depressive disorder. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with depressive disorder because it currently carries clinical signal support. Linked drugs include EVT-101, RISLENEMDAZ. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGlutamate receptor ionotropic, NMDA 1
Review this target as Glutamate NMDA receptor; GRIN1/GRIN2B, mapped to UniProt Q05586. ChEMBL maps the protein component as Glutamate receptor ionotropic, NMDA 1. Sequence length is 938 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Glutamate NMDA receptor; GRIN1/GRIN2B as ChEMBL target CHEMBL1907603, mapped to UniProt Q05586. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Glutamate NMDA receptor; GRIN1/GRIN2B is the right protein anchor across sources, using UniProt Q05586 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why depressive disorder is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Glutamate NMDA receptor; GRIN1/GRIN2B |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | Q05586 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Glutamate receptor ionotropic, NMDA 1 |
| UniProt Accession | Q05586 |
| Component Type | Protein |
| Sequence Length | 938 aa |
Glutamate receptor ionotropic, NMDA 1
Review this target as Glutamate NMDA receptor; GRIN1/GRIN2B, mapped to UniProt Q05586. ChEMBL maps the protein component as Glutamate receptor ionotropic, NMDA 1. Sequence length is 938 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Glutamate NMDA receptor; GRIN1/GRIN2B shows clinical signal disease relevance led by depressive disorder. 5 more disease programs remain visible in the same review block.
Start review with depressive disorder because it currently carries clinical signal support. Linked drugs include EVT-101, RISLENEMDAZ. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL416690 | 9.4 | Ki | 0.4 | Preclinical |
| CHEMBL423244 | 9.3 | Ki | 0.5 | Preclinical |
| CHEMBL159675 | 9.22 | Ki | 0.6 | Preclinical |
| CHEMBL65693 | 9.17 | Ki | 0.68 | Preclinical |
| CHEMBL158737 | 9.15 | Ki | 0.7 | Preclinical |
| CHEMBL274422 | 9.15 | IC50 | 0.7 | Preclinical |
| CHEMBL65693 | 9.14 | IC50 | 0.72 | Preclinical |
| CHEMBL159762 | 9.1 | Ki | 0.8 | Preclinical |
| CHEMBL65454 | 9.09 | Ki | 0.82 | Preclinical |
| CHEMBL68134 | 9.07 | Ki | 0.85 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 64 | 1,819 | 6.9 |
| protein complex format | 7 | 23 | 6.7 |
| assay format | 1 | 141 | 6.6 |
| single protein format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 16 | 68 | 6.7 |
| assay format | 5 | 27 | 7.4 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |